A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry.
María Asunción Esteve-PastorJose Miguel Rivera-CaravacaMartín Ruiz-OrtizJavier MuñizInmaculada Roldán-RabadánDéborah OteroRaquel López-GálvezÁngel CequierVicente Bertomeu-MartínezLina BadimónManuel AnguitaGregory Y H LipFrancisco Marínnull nullPublished in: Expert opinion on pharmacotherapy (2022)
In the absence of randomized, controlled head-to-head comparisons between DOACs, high-quality observational data can provide useful information on the comparative effectiveness of DOACs. Current clinical guidelines recommend the management of oral anticoagulation in AF patients with DOACs over VKA for stroke prevention; however, many guidelines generally do not suggest a specific DOAC choice in clinical practice. The revised evidence in this manuscript and our real experience reflects that apixaban and dabigatran show the best efficacy and safety profile.
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- oral anticoagulants
- clinical practice
- catheter ablation
- left atrial
- left atrial appendage
- optic nerve
- heart failure
- double blind
- percutaneous coronary intervention
- placebo controlled
- healthcare
- clinical trial
- phase iii
- randomized controlled trial
- decision making
- mitral valve
- machine learning
- combination therapy
- social media
- phase ii
- left ventricular
- data analysis
- aortic valve